This product is a CXCL10 encoding oncolytic vaccinia virus, which is based on VACV-WR with E3L and K3L double deleted.Protein E3 plays a role in the inhibition of multiple cellular antiviral responses activated by dsRNA, such as inhibition of PKR activation, apoptosis, and IFN-mediated antiviral activities. Protein K3 acts as a pseudosubstrate for EIF2AK2/PKR kinase. Inhibits therefore eIF-2-alpha phosphorylation by host EIF2AK2/PKR kinase and prevents protein synthesis shutoff.The double deletion of E3L and K3L with oncolytic-rendered modifications could enhance an immune response to a poxvirus vaccine.This product can be used in oncolytic virotherapy research and vaccinie application.
Specifications
Family
Poxviridae
Species
Vaccinia virus
Serotype
Western Reserve
Backbone
VACV-WR (ΔE3L,ΔK3L)
Backbone Background
VACV-WR strain derived from Wyeth through passaging in mice and shown high tumor selectivity and strong oncolytic effect in mouse models.The engineered VACV-WR could further enhance the immune activity and the efficacy of cancer therapies.
This antimicrobial gene encodes a chemokine of the CXC subfamily and ligand for the receptor CXCR3. Binding of this protein to CXCR3 results in pleiotropic effects, including stimulation of monocytes, natural killer and T-cell migration, and modulation of adhesion molecule expression.
Customer Reviews and Q&As
There are currently no customer reviews or questions for CXCL10-expressing Oncolytic Vaccinia Virus Western Reserve (ΔE3L,ΔK3L), pSL-(CXCL10) (CyOV-0212WQ). Click the button below to contact us or submit your feedback about this product.
All products and services are for Research Use Only. Not For Clinical Use.
Datasheet